| Literature DB >> 35004535 |
Sirajudeen S Alavudeen1, Anas Ali Asiri1, Shatha Abdulrahman Fageeh1, Ahmed Abdoh Aljarie2, Mir Javid Iqbal3, Noohu Abdulla Khan1, Fauzia Tabassum4, Mohamed Rahamathulla5, Umme Hani5, Md Sayeed Akhtar1.
Abstract
Complications of urinary tract infections (UTIs) like kidney failure and septicaemia develop once infections spread from the upper urinary tract to other parts of the body by haematogenous dissemination and they pose great health and economic burden to the countries. This retrospective study was conducted among 132 patients with bacterial UTIs in the inpatient department of tertiary care hospital in Abha, Saudi Arabia. During the study period, Escherichia coli (E. coli) and Klebsiella pneumonia (K. pneumonia) along with other 15 different bacteria were isolated. A significant difference (P < 0.05) was observed between the male and female children population in different age groups. We observed fever (84.09%) as a major symptom (P < 0.05), and seizure (9%) was reported as a major concomitant condition among UTI cases. Around 31.82% of E. coli was found to be the most common uropathogens in pediatric cases followed by 25% in K. pneumoniae. E. coli was observed to be more susceptible (92.86%) to amikacin, ceftriaxone, levofloxacin, ertapenem, gentamycin, meropenem, piperacillin-tazobactam, tigecycline, and ceftazidime. However, meropenem, tigecycline, and amikacin were observed to be effective in 100% of cases of K. pneumoniae. Meanwhile, cephalosporins were the most commonly prescribed drug category among different classes of drugs. Almost 99% of pediatric cases, based on their age, were admitted to the ward, and drugs were administered intravenously. We concluded that microbiology laboratory evidence on the causative organisms and choice of treatment together allows tailoring appropriate treatment regimens in conjunction with clinical experiences.Entities:
Keywords: Escherichia coli; antibacterial resistance; pediatric; sensitivity pattern; urinary tract infections
Year: 2021 PMID: 35004535 PMCID: PMC8734635 DOI: 10.3389/fped.2021.740106
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Distribution of urinary tract infection cases according to age.
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
| ||
| Male | 24 (18.18) | 36 (27.27) | 9 (27.27) | 6 (27.27) | 0.001 |
| Female | 12 (9.09) | 21 (15.91) | 6 (4.55) | 18 (13.64) | |
| Total (%) | 36 (13.64) | 57 (43.18) | 15 (11.36) | 24 (18.18) | |
N and % represents number and percentage respectively. P value < 0.05 was considered as statistically significant difference.
Presence of symptoms, concomitant conditions, and pathogen distributions among children with urinary tract infections.
|
|
|
| |
|---|---|---|---|
|
| |||
| Fever | 111 | 84.09* | |
| Diarrhea | 24 | 18.18 | |
| Cough | 6 | 4.55 | |
| Vesicoureteral reflux | 3 | 2.27 | |
| Chronic diarrhea | 3 | 2.27 | |
| Vomiting | 9 | 6.82 | |
| Crying during micturition | 3 | 2.27 | |
| Bronchiolitis | 6 | 4.55 | |
|
| |||
| Seizure | 12 | 9.09 | |
| Developmental dysplasia of the hip | 6 | 4.54 | |
| End stage renal disease | 3 | 2.27 | |
| Coronary heart disease | 3 | 2.27 | |
| Hypertension, hydronephrosis | 3 | 2.27 | |
| Post cardiac arrest, Covid-19 | 3 | 2.27 | |
| Hypothyroidism | 3 | 2.27 | |
| Broncho pneumonia | 3 | 2.27 | |
| Convulsion-Dany walker syndrome-glaucoma | 3 | 2.27 | |
| Pneumonia | 3 | 2.27 | |
| Bladder mass | 3 | 2.27 | |
| Cyanosis | 3 | 2.27 | |
| Bilateral hydronephrosis | 3 | 2.27 | |
| Hydronephrosis | 3 | 2.27 | |
| Hydrocephalus | 3 | 2.27 | |
| Microcytic anemia | 3 | 2.27 | |
| None | 72 | 54.54545 | |
|
| |||
|
| |||
|
| |||
| 42 | 31.82 | ||
|
| 33 | 25.00 | |
|
| 9 | 6.82 | |
|
| 9 | 6.82 | |
|
| 6 | 4.55 | |
|
| 6 | 4.55 | |
| 3 | 2.27 | ||
|
| 3 | 2.27 | |
|
| 3 | 2.27 | |
|
| 3 | 2.27 | |
|
| 3 | 2.27 | |
|
| 3 | 2.27 | |
| 3 | 2.27 | ||
|
| 3 | 2.27 | |
|
| 3 | 2.27 | |
N and % represents number and percentage respectively. P value < 0.05 was considered as statistically significant difference.
Antibiotic sensitivity pattern of common uropathogens in urinary tract infections.
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Amikacin | 39 | 92.86 |
| 72.73 | 6 | 66.67 | – | 6 | 100 | |
| AM-CL | 21 | 50.00 | 9 | 27.27 | – | – | – | – | – | |
| Ampicillin | 0 | 00.00 | 0 | 0.00 | – | – | 3 | 33.33 | – | – |
| Cefepime | 33 | 78.57 | 6 | 18.18 | 9 | 100.00 | – | 6 | 100 | |
| Cefoxitin | 30 | 71.43 | 15 | 45.45 | – | – | – | – | – | |
| Ceftriaxone | 39 | 92.86 | 6 | 18.18 | – | – | – | – | – | |
| Cefuroxime | 18 | 42.86 | 6 | 18.18 | – | – | – | – | – | |
| Ciprofloxacin | 30 | 71.43 | 12 | 36.36 | 9 | 100.00 | – | 6 | 100 | |
| Levofloxacin | 39 | 92.86 | 18 | 54.55 | 9 | 100.00 | 3 | 33.33 | 6 | 100 |
| Ertapenem | 39 | 92.86 | 21 | 63.64 | – | – | – | 6 | 100 | |
| Gentamicin | 39 | 92.86 | 15 | 45.45 | 9 | 100.00 | 3 | 33.33 | 6 | 100 |
| Imipenem | 33 | 78.57 | 18 | 54.55 | 6 | 66.67 | – | – | – | |
| Meropenem | 39 | 92.86 | 33 | 100.00 | 6 | 66.67 | – | 6 | 100 | |
| Nitrofurantoin | 18 | 42.86 | 15 | 45.45 | – | – | 3 | 33.33 | – | – |
| Piperacillin-Tazobactam | 39 | 92.86 | 15 | 45.45 | 9 | 100.00 | – | 6 | 100 | |
| Tigecycline | 39 | 92.86 | 27 | 81.82 | – | – | 9 | 100.00 | 6 | 100 |
| Co-trimoxazole | 33 | 78.57 | 21 | 63.64 | – | – | – | 6 | 100 | |
| Cefotaxime | 30 | 71.43 | 18 | 54.55 | – | – | 3 | 33.33 | – | |
| Ceftazidime | 39 | 92.86 | 6 | 18.18 | 9 | 100.00 | – | 6 | 100 | |
| Fosfomycin | 6 | 14.29 | 12 | 36.36 | – | – | – | – | – | |
| Quinupristin/ Dalfopristin | – | – | – | – | – | – | 6 | 66.67 | – | – |
| Linezolid | – | – | – | – | – | – | 9 | 100.00 | – | – |
| Vancomycin | – | – | – | – | – | – | 9 | 100.00 | – | – |
| Teicoplanin | – | – | – | – | – | – | 6 | 66.67 | – | – |
| Streptomycin (High dose) | – | – | – | – | – | – | 3 | 33.33 | – | – |
| Aztreonam | – | – | – | – | 6 | 66.67 | – | 6 | 100 | |
| Colistin | – | – | – | – | 3 | 33.33 | – | – | – | |
| Clindamycin | – | – | – | – | – | – | – | – | – | |
| Daptomycin | – | – | – | – | – | – | – | – | – | |
| Tobramycin | – | – | – | – | – | – | – | 6 | 100 | |
|
| ||||||||||
| Staphylococcus aureus | Ciprofloxacin, Clindamycin, Daptomycin, Erythromycin, Fosfomycin, Linezolid, Moxifloxacin, Mupirocin, Rifampin, Synercid, Teicoplanin, Tetracycline, and Vancomycin | |||||||||
| Enterobacter cloacae | Amikacin, Ciprofloxacin, Gentamicin, Levofloxacin, Meropenem, Norfloxacin, and Tobramycin | |||||||||
| Acinetobacter MDR* | Vancomycin, Ceftazidime, and Rifampin | |||||||||
| Staphylococcus epidermidis | Vancomycin, Tetracycline, Nitrofurantoin, Rifampicin, and Bactrim | |||||||||
| Acinetobacter baumannii complex | Colistin-tigecycline | |||||||||
| Stenotrophomonas maltophilia | Ceftazidime, Levofloxacin, and Co-trimoxazole | |||||||||
N and % represents number and percentage respectively about sensitivity for each isolated organism. AM-CL, Amoxicillin-Clavulanic acid; E. coli, Escherichia coli; K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa, Pseudomonas aeruginosa; E. faecium, Enterococcus faecium; K. oxytoca, Klebsiella oxytoca.
Usage of antibiotics in different cases of urinary tract infections.
|
|
|
|
|
|---|---|---|---|
| Penicillin | Amikacin | 6 | 4.55 |
| Gentamicin | 3 | 2.27 | |
| Amoxicillin/ | 3 | 2.27 | |
| Potassium Clavulanate | |||
| Ampicillin | 15 | 11.36 | |
| Cephalosporins | Ceftriaxone | 39 | 29.55 |
| Cefuroxime | 21 | 15.91 | |
| Cefotaxime | 18 | 13.64 | |
| Ceftazidime | 9 | 6.82 | |
| Fluroquinolones | Ciprofloxacin | 3 | 2.27 |
| Levofloxacin | 3 | 2.27 | |
| Tetracycline | Tigecycline | 3 | 2.27 |
| Sulphonamides | Co-trimoxazole | 12 | 9.09 |
| Polymyxins | Colistin | 3 | 2.27 |
| Macrolides | Clindamycin | 9 | 6.82 |
| Azithromycin | 6 | 4.55 | |
| Anti-mycobacterial | Rifampin | 9 | 6.82 |
| Meropenem | 27 | 20.45 | |
| Others | Nitrofurantoin | 3 | 2.27 |
| Linezolid | 6 | 4.55 | |
| Vancomycin | 33 | 25 |
N and % represents number and percentage respectively about usage of antibiotics in different cases of urinary tract infections.